ARCHIVES

FDA, NCI Remain At Odds Over Drug approval Guidelines Despite Reconciliation Discussion

This article is from The Cancer Letter archive.

Vol. 13 No. 39 | October 9, 1987

Download PDF Visit The Full Archive

Related Articles

MSKCC hopes to raise $1 billion in five-year campaign.

November 7, 2003

Central Line Safety Intervention Lowers Patient Infection Rate

October 25, 2013

In Brief: Ross, Harvey To Lead Cancer Center Group; NCI Director In Office By Aug. 1, Varmus Says

May 19, 1995

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

January 25, 2013

In Congress: HHS Hasn’t Identified Another Source For NIH Increase If Tobacco Bill Not Passed: Shalala

March 6, 1998

Flat NIH Budget Threatens Future Of Research, Universities Say.

March 14, 2008